Last reviewed · How we verify
NCT05199142
A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline
Phase 1 trial testing SDI-118 in Cognitive Decline in 5 participants. Terminated before completion.
11 March 2022
Quick facts
| Lead sponsor | Syndesi Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 23 September 2021 |
| Primary completion | 11 March 2022 |
| Estimated completion | 11 March 2022 |
| Sites | 2 locations across United Kingdom, Germany |
Drugs / interventions tested
- SDI-118 — full drug profile →
- Placebo
Conditions studied
- Cognitive Decline — all drugs for Cognitive Decline →
Sponsor
Syndesi Therapeutics
Who can join
Adults 65 to 85, any sex, with Cognitive Decline. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on elderly male and female study participants with cognitive decline at screening.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in synaptic PET imaging and intervention with synapse-targeted small-molecular drugs for dementia diagnosis and therapy.
Lu X, Ji B, Huang G, Ding H. · · 2025 · cited 1× · PMID 40166112 · DOI 10.1016/j.fmre.2024.04.013
Verify or expand the search:
- PubMed search for NCT05199142
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SDI-118
Trials testing the same drug.
- NCT05212116 — A Study of SDI-118 in Participants in Remission From Depression · Phase 1 · withdrawn
- NCT05486195 — A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and · Phase 1 · completed
Other recruiting trials for Cognitive Decline
Currently open trials in the same condition.
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT07394504 — Effects of Turning Based Dual Task Training on Balance and Mild Cognitive Impairment in Diabetic Peripheral Neuropathy · NA · recruiting
- NCT07127965 — Exercise Adherence and Cognitive Decline: Phase 2 · NA · recruiting
- NCT07151365 — Plant-based Diets and Healthy Aging · recruiting
- NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting
Other Syndesi Therapeutics trials
Trials by the same sponsor.
- NCT05212116 — A Study of SDI-118 in Participants in Remission From Depression · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05199142 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Syndesi Therapeutics
- Last refreshed: 22 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05199142.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing